BioNTech SE (22UA) Financial Statements
BioNTech SE Financial Overview
BioNTech SE's market cap is currently $19.83B. The company's EPS TTM is $-6.73; its P/E ratio is -11.50; BioNTech SE is estimated to report earnings on November 3, 2026, and the estimated EPS forecast is $0.67. See an overview of income statement, balance sheet, and cash flow financials.
| Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 | |
|---|---|---|---|---|---|
| Income Statement | |||||
| Total Revenue | $ 2.76B | $ 2.75B | $ 3.82B | $ 17.31B | $ 18.98B |
| Gross Profit | $ 2.14B | $ 2.21B | $ 3.22B | $ 14.32B | $ 16.07B |
| Operating Income | $ -623.87M | $ -1.31B | $ 690.40M | $ 12.64B | $ 15.28B |
| EBITDA | $ -628.00M | $ -367.10M | $ 1.38B | $ 13.10B | $ 15.00B |
| Net Income | $ -1.09B | $ -665.30M | $ 930.30M | $ 9.43B | $ 10.29B |
| Balance Sheet | |||||
| Cash & Short-Term Investments | $ 14.83B | $ 16.78B | $ 16.55B | $ 14.06B | $ 2.07B |
| Total Assets | $ 21.98B | $ 22.53B | $ 23.01B | $ 23.28B | $ 15.83B |
| Total Debt | $ 267.29M | $ 254.20M | $ 219.10M | $ 212.20M | $ 301.50M |
| Net Debt | $ -7.40B | $ -9.51B | $ -11.44B | $ -13.66B | $ -1.39B |
| Total Liabilities | $ 2.76B | $ 3.12B | $ 2.76B | $ 3.22B | $ 3.94B |
| Stockholders' Equity | $ 19.22B | $ 19.41B | $ 20.25B | $ 20.06B | $ 11.89B |
| Cash Flow | |||||
| Free Cash Flow | $ 269.81M | $ -244.60M | $ 4.67B | $ 13.21B | $ 735.70M |
| Operating Cash Flow | $ 438.00M | $ 207.70M | $ 5.37B | $ 13.58B | $ 889.70M |
| Investing Cash Flow | $ -2.37B | $ -2.08B | $ -6.95B | $ -35.30M | $ -566.10M |
| Financing Cash Flow | $ -50.81M | $ -45.90M | $ -778.60M | $ -1.42B | $ 94.20M |
Currency in EUR
